Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
January 1, 1990
The influence of rejection episodes on the development of coronary artery disease after heart transplantation
A Schütz, B M Kemkes, C Kugler, et al.
BMC Genomics
|
February 12, 2013
Genotyping 1000 yeast strains by next-generation sequencing
Stefan Wilkening, Manu M Tekkedil, Gen Lin, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 20, 2010
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
S Björkman, V S Blanchette, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 5, 2014
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study
J Windyga, T Lissitchkov, O Stasyshyn, et al.
Gastroenterologie Clinique Et Biologique
|
February 19, 2000
[Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients]
D Rey, S Fritsch, C Schmitt, et al.
Vaccine
|
April 21, 2006
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies
A Loew-Baselli, R Konior, B G Pavlova, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 10, 2013
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
J Windyga, T Lissitchkov, O Stasyshyn, et al.
Genetics
|
December 31, 2013
An evaluation of high-throughput approaches to QTL mapping in Saccharomyces cerevisiae
Stefan Wilkening, Gen Lin, Emilie S Fritsch, et al.
Bone Marrow Transplantation
|
February 3, 2015
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma
A-K Zoellner, S Fritsch, D Prevalsek, et al.
Bone Marrow Transplantation
|
May 14, 2014
Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation
J Tischer, N Engel, S Fritsch, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
January 1, 1990
The influence of rejection episodes on the development of coronary artery disease after heart transplantation
A Schütz, B M Kemkes, C Kugler, et al.
BMC Genomics
|
February 12, 2013
Genotyping 1000 yeast strains by next-generation sequencing
Stefan Wilkening, Manu M Tekkedil, Gen Lin, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 20, 2010
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
S Björkman, V S Blanchette, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 5, 2014
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study
J Windyga, T Lissitchkov, O Stasyshyn, et al.
Gastroenterologie Clinique Et Biologique
|
February 19, 2000
[Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients]
D Rey, S Fritsch, C Schmitt, et al.
Vaccine
|
April 21, 2006
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies
A Loew-Baselli, R Konior, B G Pavlova, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 10, 2013
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
J Windyga, T Lissitchkov, O Stasyshyn, et al.
Genetics
|
December 31, 2013
An evaluation of high-throughput approaches to QTL mapping in Saccharomyces cerevisiae
Stefan Wilkening, Gen Lin, Emilie S Fritsch, et al.
Bone Marrow Transplantation
|
February 3, 2015
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma
A-K Zoellner, S Fritsch, D Prevalsek, et al.
Bone Marrow Transplantation
|
May 14, 2014
Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation
J Tischer, N Engel, S Fritsch, et al.
Page
of 12